HK Stock Market Move | RIMAG GROUP (02522) rises nearly 4% with several directors increasing their holdings, "Artificial Intelligence + Medical Health" welcomes new policies.

RIMAG GROUP (02522) rose by almost 4%, rising 3.96% as of the time of writing to HK$16.55, with a trading volume of HK$87.4613 million. On the news front, RIMAG GROUP announced that the board of directors had learned that on November 3 and 4, Chairman and Executive Director Chen Zhaoyang, Executive Director and Vice President, Joint Company Secretary, and Board Secretary He Yingfei, and Executive Director, Vice President, and CFO Feng Xie had purchased a total of approximately 96,500 H shares of the company in the open market with their own funds. The directors stated that this decision to increase their holdings was based on the recent progress made by the group in the field of regional medical image sharing centers, medical image data services, as well as the professional capabilities and high recognition of research and development technology demonstrated by the group in building the entire smart medical imaging industry chain of "data + AI/algorithm + application scenario". It is worth noting that on November 4, the National Health Commission, the National Development and Reform Commission, and five other departments issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Medical Health' Applications", which mentioned that by 2030, basic coverage of intelligent assistive applications for primary medical care will basically be achieved, promoting the widespread use of artificial intelligence technology applications such as medical image intelligent assistive diagnosis and clinical diagnostic decision-making in hospitals at and above the secondary level. The standard system for "Artificial Intelligence + Medical Health" applications will be basically improved, and a number of globally leading technology innovation and talent development bases will be established.